Clinical trials: Single Dose
IPF
A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects
The purpose of this study is to investigate the safety, PK, and immunogenicity of a single intravenous administration of HLX6018 in healthy subjects, based on the preliminary efficacy and safety established through in vitro and…
- Trial name
- NCT06310746
- Testing
- GARP/TGF-β1 monoclonal antibody
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
Healthy Participants
First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants
This is a first-in-human study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-579 in healthy male and female adult participants.
- Trial name
- NCT07412288
- Testing
- KT-579
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Kymera Therapeutics, Inc.
Common Cold, Infections, Upper Respiratory Tract
Acute Cough Study In Children
15 mg dextromethorphan hydrobromide will be better than placebo with respect to reducing the number of coughs over 6 hours and reducing the subjective severity of cough over 6 hours.
- Trial name
- NCT01257542
- Testing
- Dextromethorphan
- Where
- 4 sites in United States
- Volunteers
- 140 people
- Sponsor
- Pfizer
Healthy
A Study to Assess Mass Balance Recovery, Metabolite Profile and Identification of IV and Oral 14C-BC-3781
This is a single-centre, open-label, non-randomized, single dose study in healthy male subjects designed to assess mass balance recovery, metabolite profile and metabolite identification of radio-labeled BC-3781 administered via…
- Trial name
- NCT03131141
- Testing
- BC-3781
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Nabriva Therapeutics AG
Hyperlipidemias
A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-221 in healthy male subjects.
- Trial name
- NCT05202405
- Testing
- AD-221, AD-221A and AD-221B
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Healthy Volunteers
Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeat Oral Doses of GSK3008356 in Healthy and Obese Subjects
This study is a phase I, randomized, placebo-controlled, double-blind (sponsor unblind), three part study. The primary objective of the study is to characterize the safety, and tolerability of GSK3008356 single dose, 14 daily…
- Trial name
- NCT02742766
- Testing
- GSK3008356
- Where
- Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatic Function Abnormal
Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function
This is a Phase 1, parallel, open-label, 3-arm study to investigate the pharmacokinetic (PK) parameters of amcenestrant in female participants aged 40 to 75 years with mild and moderate hepatic impairment, and in matched…
- Trial name
- NCT05126329
- Testing
- amcenestrant
- Where
- 3 sites in Germany, South Korea
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Sanofi
Pharmacology, Clinical
Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose in Participants With Liver Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
Neladenoson bialanate is currently under clinical development for a condition in which the heart has trouble pumping blood through the body (chronic heart failure).
- Trial name
- NCT04322253
- Testing
- Neladenoson bialanate (BAY 1067197)
- Where
- Germany
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bayer
Primary Hyperoxaluria
Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria
This is a double-blind, placebo-controlled, dose escalation trial of DCR-PHXC in Healthy Volunteers (HVs) and patients with Primary Hyperoxaluria (PH).
- Trial name
- NCT03392896
- Testing
- DCR-PHXC
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Drug Interaction Potentiation
Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin
This is a Phase 1, two-part, open-label study to evaluate the interaction of cyclosporine, probenecid, and rifampin as perpetrators with vadadustat (victim) in healthy male and female subjects.
- Trial name
- NCT03801746
- Testing
- vadadustat, Rifampin, Probenecid
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Healthy Volunteers
Trial on Single/Multiple Ascending Doses for Safety, PK and PD for CBP-0276 in Healthy Subjects
A double-blind, randomized, placebo-controlled, single and multiple ascending dose study with food effect to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CBP-0276.
- Trial name
- CBP276SADMAD (NCT07708831)
- Testing
- CBP-0276 Acetate
- Where
- 2 sites in Mexico
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Clarent Biopharma, Inc.
Acute Pharyngitis, Sore Throat
Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method
The study's purpose is to demonstrate the onset of action, i.e., time to meaningful pain relief in patients with pharyngitis, of flurbiprofen 8.75 mg lozenge using the Double-Stopwatch Method (DSW).
- Trial name
- NCT01986361
- Testing
- flurbiprofen
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Reckitt Benckiser LLC
Thromboembolism
Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder
CV185118 is a single dose Apixaban PK/PD study in pediatric participants. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric participants at risk for thrombosis
- Trial name
- NCT01707394
- Testing
- Apixaban
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 49 people
- Sponsor
- Bristol-Myers Squibb
Parkinson Disease
Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics
The purpose of the study was to To investigate whether the administration of BIA 6-512 (25 mg, 50 mg, 75 mg and 100 mg) at steady-state affects the pharmacokinetics of levodopa when administered in combination with a single-dose…
- Trial name
- NCT03094156
- Testing
- BIA 6-512, Madopar® 250, Comtan®
- Where
- Portugal
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Neisseria Meningitidis, Meningococcal Infections
Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia
This study will be conducted among adolescents in Saudi Arabia who previously received one dose of A, C, Y, W 135 and at least one dose of A, C meningococcal polysaccharide vaccine.
- Trial name
- NCT00444951
- Testing
- Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine, Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine
- Where
- 7 sites in Saudi Arabia
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Iron Deficiency Anemia
A Single Ascending Study of IOP Injection in Patients With Iron Deficient Anemia
The purpose is to evaluate the efficacy and safety of IOP Injection (MPB-1514) for the treatment of iron-deficient anemia (IDA).
- Trial name
- NCT03485053
- Testing
- IOP Injection / MPB-1514
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- MegaPro Biomedical Co. Ltd.
Healthy Participants
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants
The purpose of this study is to assess the safety and tolerability of TAK-994 following single and multiple oral doses in healthy non-Japanese and Japanese adult participants and healthy elderly participants.
- Trial name
- NCT03933488
- Testing
- TAK-994
- Where
- 2 sites in United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Takeda
Non Small Cell Lung Cancer, Triple Negative Breast Cancer
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
- Conditions
- Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
- Trial name
- NCT03504488
- Testing
- CAB-ROR2-ADC, PD-1 inhibitor
- Where
- 59 sites in United States, Greece and 4 more
- Volunteers
- 132 people
- Sponsor
- BioAtla, Inc.
Healthy
Pharmacokinetics, Safety, and Tolerability Study of the Autoinjector and Pre-filled Syringe of SB4 in Healthy Male Subjects
The purpose of this study is to compare the pharmacokinetics, safety, and tolerability of the autoinjector and pre-filled syringe of SB4 in healthy male subjects.
- Trial name
- NCT03193203
- Testing
- Etanercept
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Samsung Bioepis Co., Ltd.
Dry Eye Syndromes
Pharmacokinetics, Safety, and Tolerability of rhEGF Eye Drops in Healthy Male Subjects
A randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of the Pharmacokinetics, safety, and tolerability of rhEGF eye drops in healthy male subjects
- Trial name
- NCT05219461
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Daewoong Bio Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.